Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor
Open accessThe DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index; 25 of the 72 sources its claims cite were checked for support.
Abstract
Cellular senescence suppresses cancer by arresting cell proliferation, essentially permanently, in response to oncogenic stimuli, including genotoxic stress. We modified the use of antibody arrays to provide a quantitative assessment of factors secreted by senescent cells. We show that human cells induced to senesce by genotoxic stress secrete myriad factors associated with inflammation and malignancy. This senescence-associated secretory phenotype (SASP) developed slowly over several days and only after DNA damage of sufficient magnitude to induce senescence. Remarkably similar SASPs developed in normal fibroblasts, normal epithelial cells, and epithelial tumor cells after genotoxic stress in culture, and in epithelial tumor cells in vivo after treatment of prostate cancer patients with DNA-damaging chemotherapy. In cultured premalignant epithelial cells, SASPs induced an epithelial-mesenchyme transition and invasiveness, hallmarks of malignancy, by a paracrine mechanism that depended largely on the SASP factors interleukin (IL)-6 and IL-8. Strikingly, two manipulations markedly amplified, and accelerated development of, the SASPs: oncogenic RAS expression, which causes genotoxic stress and senescence in normal cells, and functional loss of the p53 tumor suppressor protein. Both loss of p53 and gain of oncogenic RAS also exacerbated the promalignant paracrine activities of the SASPs. Our findings define a central feature of genotoxic stress-induced senescence. Moreover, they suggest a cell-nonautonomous mechanism by which p53 can restrain, and oncogenic RAS can promote, the development of age-related cancer by altering the tissue microenvironment.
Overview
CoChat Summary
TL;DR
Senescent human fibroblasts and epithelial cells develop a complex senescence-associated secretory phenotype (SASP) that can promote malignant phenotypes in neighboring cells, including epithelial–mesenchymal transition (EMT) and invasion. Oncogenic RAS and loss of p53 amplify and accelerate this SASP, suggesting p53 acts as a cell-nonautonomous tumor suppressor by restraining protumorigenic secreted factors.
Key findings
- Of 120 proteins assayed, 41 were significantly oversecreted by senescent cells compared with presenescent cells, while 79 showed no significant difference; the SASP included inflammatory cytokines/chemokines, growth factors, shed surface molecules, and survival factors.
- The SASP was conserved across cell types: normal fibroblasts and normal prostate epithelial cells overlapped significantly (p ≈ 10⁻³; r = 0.53; >66% overlap), and 24 proteins were shared between all fibroblast and all epithelial SASPs (p ≈ 10⁻⁵).
- SASP induction required genotoxic stress sufficient to cause senescence: 10 Gy X-irradiation induced a SASP, whereas 0.5 Gy did not; the SASP developed slowly, requiring 4–7 d after irradiation.
- Oncogenic RAS induced an amplified SASP: correlations with REP/XRA SASPs were 0.75 for WI-38/IMR-90 and 0.84 for HCA-2 fibroblasts; nine proteins were significantly more secreted in SEN(RAS) versus SEN(REP;XRA) across all fibroblasts, plus five RAS-unique proteins.
- p53 loss was not required to initiate or maintain a SASP, but it amplified it: a subset of SASP proteins was secreted at 5- to 30-fold higher levels after p53 inactivation, and combined p53 loss plus oncogenic RAS produced the most amplified SASP, with accelerated development within 2–4 d.
- SASP factors induced EMT and invasion in nonaggressive breast cancer cells; IL-6 and IL-8 blocking antibodies reduced SEN CM–stimulated invasion.
- In human prostate cancer biopsies after mitoxantrone chemotherapy, tumors showed higher p16INK4a and p21 mRNAs, lower cyclin A, MCM-3, and PCNA mRNAs, and higher mRNAs for IL-6, IL-8, GM-CSF, GRO-α, IGFBP-2, and IL-1β, while IL-2 mRNA did not significantly change.
Methods
- Human fibroblast strains (WI-38, IMR-90, BJ, HCA2, hBF184), normal prostate epithelial cells (PrECs), and prostate tumor lines (BPH1, RWPE1, PC3) were induced to senesce by replicative exhaustion (REP), 10 Gy X-irradiation (XRA), oncogenic RAS, or mitoxantrone (MIT); p53 was inactivated using GSE22 or shRNA.
- Conditioned media were analyzed with modified antibody arrays detecting 120 proteins, using ³⁵S-streptavidin detection for improved dynamic range; findings were validated by ELISA, immunostaining, invasion assays, and RT-PCR.
- Human prostate cancer biopsies were obtained before and after MIT chemotherapy; approximately 1,000 tumor epithelial cells were laser-captured per sample, and mRNA was quantified by RT-PCR. Statistical analyses used Pearson correlation, two-tailed Student t-test, and hypergeometric distribution for SASP overlap.
Limitations
- The paper does not include a formal limitations section.
- Evident from the text: the in vivo human SASP evidence relies on mRNA from laser-captured tumor cells rather than direct measurement of secreted proteins, with approximately 1,000 cells captured per sample.
- Evident from the text: many mechanistic conclusions come from cultured cells, and the SASP is described as not a fixed phenotype, with quantitative and qualitative differences among cell strains, tissues, and donors.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 Chemotherapy-Induced SASP in Culture and In Vivo (A) Overall correlation between XRA and mitoxantrone (MIT)-induced SASPs for all three prostate epithelial cancer cell lines (BPH-1, RWPE-1, and PC-3). Correlations for the individual cell lines are given in the table to the right. The senescence inducer (XRA or MIT) is given in parentheses. (B–E) Human tumor cells were isolated from biopsies obtained from the same patient before MIT chemotherapy and from prostate tissue following prostatectomy after MIT chemotherapy. Laser captured cells were analyzed by quantitative RT-PCR for the mRNAs encoding the indicated proteins, as described in Materials and Methods and Text S1. The results are displayed on a log10 scale indicating the values before (horizontal or x-axis) compared to after (vertical or y-axis) chemotherapy (top left panel in [B]). Each black dot in (B, C, and D) represents the results obtained from a single patient. The average values for all patients before versus after chemotherapy are indicated by a red dot (B–D); these values are also represented as a heat map in (E). (B) Values for mRNAs encoding proteins associated with senescence (p16 and p21) and proliferation (cyclin A, MCM-3, and PCNA). (C) Values for mRNAs encoding SASP-associated proteins (IL-6, IL-8, GM-CSF, GRO-α, IGFBP-2, and IL-1β). (D) Value for an mRNA encoding a non-SASP–associated protein (IL-2). (E) Averages for the values shown in (B–D). Overall p-values, determined by the Student t-test, and number of paired samples (or patients) analyzed for each mRNA are given to the right of the heat map. Signals higher than the prechemotherapy baseline are shown in red; signals below baseline are displayed in green.](https://figures.cochat.ai/paper-figures/92013b1ef9b3492d8c26b76b40577c28/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-3.jpg)


![Figure 6 p53 Restrains the SASP (A) CM containing factors secreted by the indicted cells were analyzed by antibody arrays and displayed, using PRE CM as the baseline. We pooled data from cells of the same genotype (p53 wild type or p53 deficient) under the same culture conditions. SEN indicates pooled data from cells originating from the same tissue (WI-38, IMR-90 from embryonic lung; and HCA-2, BJ from neonatal foreskin) and induced to senesce by REP or XRA. Pooling and averaging of highly correlated samples was performed as described for Figure 5, and details of the data processing are provided in Datasets S13–S16. The top four rows are the same top four rows in Figure 5A and are included to serve as a visual reference. The senescence inducer is given in parentheses. p53 status is indicated as either wild type (wt) or deficient (d) owing to either GSE22 expression or expression of an shRNA against p53. Manipulations are indicated in sequence, separated by a greater than symbol (>). The heat map key (right) indicates the log2-fold changes. Signals higher than the baseline are shown in yellow; signals below baseline are displayed in blue. Comparison between rows is accurately illustrated in (B) and (C) in which each genetically manipulated cell type is compared to its appropriate control baseline. (B) Log2-fold values for SASP factors that are significantly increased, or significantly and uniquely (as indicated by double asterisks [**]) elevated, in CM from SEN cells made p53 deficient by GSE22, using untreated wild-type SEN values as the baseline. Green indicates WI-38 cells made senescent by XRA, after which p53 was subsequently inactivated by expressing GSE22 using a lentivirus; these cells do not resume proliferation (“unreverted”) upon p53 inactivation (see Figure S6). Blue indicates WI-38 in which p16 was inactivated by an shRNA, induced to senesce by XRA, then infected with the GSE22-expressing lentivirus; these cells do revert (REV) after p53 inactivation. Pink indicates HCA2 cells made SEN by XRA, then infected with GSE22 lentivirus; these cells also revert after p53 inactivation. (C) Log2-fold values for SASP factors that are significantly increased, or significantly and uniquely (as indicated by double asterisks [**]) elevated, in CM from cells made p53-deficient (by GSE22 expression), then induced to senesce by REP, XRA, or RAS. Red indicates WI-38 and IMR90 (averaged) cells expressing GSE22, then induced to senesce by XRA or REP, using cells made SEN by XRA or REP as a baseline. Gray indicates WI-38, IMR-90, and HCA2 (averaged) expressing GSE22, then made senescent by RAS, using SEN by RAS as a baseline. (D) WI-38 cells expressing GSE22 were induced to senesce by XRA and then immunostained for the SASP proteins IL-6 and IL-8, the senescence marker p16INK4a, and p53, which accumulates in the presence of GSE22. (E) Comparative graphical representation of the secretory profiles of cells made senescent by XRA or REP (dotted line), RAS (black line), p53 inactivation (GSE22) followed by XRA or REP (blue line), or p53 inactivation (GSE22) followed by RAS (red line). The increased slopes (as indicated by the arrow)indicate amplified SASPs. (F) Hierarchical cluster analysis of all the cells analyzed in (A), plus the SASP induced by RAS (see Figure 5). RAS status is indicated as either wild type (wt) or oncogenic (o) owing to expression of Ha-RASv12. (G) WI-38 cells with wild-type (wt) or inactive (GSE) p53 were irradiated or induced to express oncogenic RAS (RAS), and CM was collected 4 or 10 d later. Soluble factors were analyzed by antibody arrays and displayed as described in Figure 1D, using PRE CM as the baseline (black column on the left; see also Figure S5C for details). Signals higher than baseline are shown in yellow; signals below baseline are in blue. n/a, not applicable. (H) Log2-fold values for prostate epithelial cell SASP factors that are significantly or uniquely (as indicated by double asterisks [**]) elevated in CM from p53-deficient cancer cells (PC3, BPH1, and RWPE1) that were induced to senesce by XRA, compared to primary p53 wild-type cells (PrECs) that were induced to senesce by XRA.](https://figures.cochat.ai/paper-figures/ec6066e9173e4732bc7f9d2c5718a2dd/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-6.jpg)
![Figure 7 Biological Activities of the Amplified SASP (A) T47D and ZR75.1 cells were incubated with the indicated CM for 3 d and then analyzed for cell scattering, immunostained for the indicated proteins, and analyzed for vimentin and actin levels by western blotting. Controls for the immunofluorescence from the same individual experiment are shown in Figure 4B. The senescence inducer is given in parentheses. p53 status was either wild type or deficient (GSE). Manipulations are indicated in sequence, separated by >. (B) Epithelial cells were incubated with CM from the indicated WI-38 cells and assayed for invasion as described in Materials and Methods and Figure 3C. Double asterisks (**) indicate p < 0.02. Error bars indicate the standard deviation around the mean. (C) Epithelial cells were incubated with CM from the indicated fibroblasts and cell number was determined by cell counting, total protein, or green fluorescent protein (GFP) fluorescence using epithelial cells expressing GFP, as described in [80]. A single asterisks (*) indicates p < 0.05. Error bars indicate the standard deviation around the mean. (D) Model for the cell-nonautonomous activities of oncogenic RAS and the p53 tumor suppressor protein. Oncogenic and genotoxic stress of sufficient magnitude to cause senescence induce a SASP, whereby cells secrete inflammatory cytokines, chemokines, and growth factors that can alter the tissue microenvironment and stimulate malignant phenotypes in nearby cells. Thus, in addition to their well-known cell-autonomous effects, oncogenes can promote cancer cell-nonautonomously by inducing a SASP. Oncogenic and genotoxic stress also activate p53, which suppresses cancer by cell-autonomous mechanisms (promoting repair, or inducing apoptosis or senescence). In addition, p53 suppresses cancer by the cell-nonautonomous effects of suppressing the intensity of the SASP and its deleterious effects.](https://figures.cochat.ai/paper-figures/c8eed762510f438c8789f2db0ec751a6/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-7.jpg)
Verification
Claims the paper makes
19 Valid · 4 Not valid · 9 Not checked · 117 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Lastly, in mice and humans, a senescence response to strong mitogenic signals, such as those delivered by certain oncogenes, prevents premalignant lesions from progressing to malignant cancers [ 16 – 19 ].”
What the sources say
- Not checked — no full text of the sourcecites [16] Collado, 2005, Nature source
- Partly supportedcites [17] Chen, 2005, Nature sourceExperimental — accuracy not yet measured
The Abstract reports that p53-dependent senescence restricts Pten-deficient tumorigenesis in mice, and the human-specimen passage reports senescence staining mainly in prostate hyperplasia or PIN rather than frank tumour (page numbers unavailable). The human observations do not establish that senescence prevents progression, and the experimental finding concerns Pten loss rather than strong mitogenic signals generally. (LLM, conf=0.86)
- Partly supportedcites [18] Michaloglou, 2005, Nature sourceExperimental — accuracy not yet measured
The discussion (Nature, vol. 436, 4 August 2005; page not provided) says the findings support oncogene-induced senescence as a mechanism in humans that limits progression of premalignant lesions. The paper studies human melanocytes and naevi, not mice, and describes limitation of progression rather than categorical prevention. (LLM, conf=0.88)
- Not matchedcites [19] Braig, 2005, Nature
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Consistent with this view, senescent cells increase with age in mammalian tissues [ 27 ]”
What the sources say
- Supportedcites [27] Campisi, 2005, Cell source
The “Cellular Senescence and Aging” passage (page not provided) says that cells with characteristics of senescence accumulate with age in multiple tissues from humans and rodents. This supports the claim about mammalian tissues. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Senescent cells acquire many changes in gene expression, mostly documented as altered mRNA abundance, including increased expression of secreted proteins [ 33 – 41 ].”
What the sources say
- Partly supportedcites [33] Zhang, 2003, Proc Natl Acad Sci U S A sourceExperimental — accuracy not yet measured
The Results report hundreds of changes in transcript abundance during senescence in human fibroblasts, supporting the claim about altered gene expression measured as mRNA. They identify up-regulated genes encoding membrane-associated proteins, but the passages in our copy do not establish increased expression of secreted proteins; membrane-associated is not the same as secreted. (LLM, conf=0.85)
- Supportedcites [34] Chang, 2002, Proc Natl Acad Sci U S A source
The Results and Discussion report many gene-expression changes in senescent HCT116 cells, measured primarily with RNA-based methods, and specifically identify increased expression of genes for secreted factors. The paper also notes parallels with senescence in normal cells. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [35] Bavik, 2006, Cancer Res source
- Not checked — no full text of the sourcecites [36] Mason, 2004, Oncogene source
- Not checked — no full text of the sourcecites [37] Wajapeyee, 2008, Cell source
- Not matchedcites [38] Kortlever, 2006, Nat Cell Biol
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not checked — no full text of the sourcecites [39] Parrinello, 2005, J Cell Sci source
- Supportedcites [40] Kuilman, 2008, Cell source
The Results (page not provided) report genome-wide expression analysis showing multiple gene classes upregulated during oncogene-induced senescence, including cytokine and chemokine genes. They also report increased IL-6 and IL-8 expression and secretion of IL-6 by senescent cells, supporting the claim about secreted proteins. (LLM, conf=0.91)
- Supportedcites [41] Acosta, 2008, Cell source
The Discussion (page unavailable) identifies increased production of various secreted proteins as a characteristic of senescent cells. It also reports that CXCR2 and many of its ligands are upregulated during senescence, supporting the claim about changes in expression. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Thus, oncogenes such as RAS, which are known to activate protumorigenic paracrine mechanisms during transformation [ 59 – 61 ], might also exert cell-nonautonomous protumorigenic effects through nontransformed cells during the process of inducing senescence ( Figure 7 D).”
What the sources say
- Supportedcites [59] Ancrile, 2007, Genes Dev source
The citation supports the sentence’s background clause about protumorigenic paracrine mechanisms during RAS-driven transformation. The Abstract says RAS-induced IL6 acts in a paracrine fashion to promote angiogenesis and tumor growth; the Summary likewise describes this effect in RAS-driven tumor cells. The later suggestion about senescence is the citing authors’ own inference, not a finding attributed to this source. (LLM, conf=0.92)
- Supportedcites [60] Yang, 2006, Proc Natl Acad Sci U S A source
The Discussion states that RAS signals to stromal cells through Gro-1, inducing senescence and promoting tumor growth or malignant transformation. The paper’s opening summary also reports that Gro-1-induced senescent fibroblasts promote tumor growth, supporting the proposed cell-nonautonomous effect. Page numbers are not provided in our copy. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [61] Akhurst, 2001, Trends Cell Biol source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Our results showed that human tumor cells very likely undergo senescence in response to DNA damaging chemotherapy in vivo, as reported for mice [ 49 ].”
What the sources say
- Supportedcites [49] Schmitt, 2002, Cell source
The citation is attached to “as reported for mice,” not to the citing authors’ finding about human tumor cells. The cited paper’s Discussion reports chemotherapy-induced senescence in vivo in a murine lymphoma model; it does not itself establish the human finding. (LLM, conf=0.93)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
89 more claims · 3 with their cited sources checked
Create a free account to see all 149 claims and every source verdict.
- Probably not a substantial claim. 18
- It may state two separate claims as one. 41
- Borderline: one of the tests for a substantial claim is unclear. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“the effects of the senescent fibroblasts were due primarily to their secretion of matrix metalloproteinases (MMPs), which are prominent SASP components (32, 94).”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Senescent cells are metabolically active and can acquire a pro-inflammatory, tissue-destructive, pro-apoptotic senescence-associated secretory phenotype (SASP) [26]”
From Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease (2019) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“although it was robustly induced 7–10 days after cultured MEFs were stimulated to senesce by IR (Coppé et al., 2008)”
From An Essential Role for Senescent Cells in Optimal Wound Healing through Secretion of PDGF-AA (2014) · cites this paper as Coppé et al., 2008
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SASP is primarily a property of cells that senesce owing to, or accompanied by, genomic damage or epigenomic perturbation.”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many types of cytotoxic chemotherapies are severe DNA-damaging agents that can induce senescence in both tumor cells and surrounding normal cells (31–34).”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Experimental — accuracy not yet measured
80 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
A biomarker that identifies senescent human cells in culture and in aging skin in vivo.
Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., & Pereira-Smith, O. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.20.9363 · Cited by 7,477
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 5×
“We thank R. Driver for support with the array experiments, J. Gray and R. Neve for discussions, cells, and use of Cellomix; A. Huang for help with the microdissection and PCR; A. Zielinski and J. Allison for technical help; T. Beer, M. Garzotto, C. Higano, L. True, R. Vessella, and the University of Washington Medical…”
BackgroundMethodInfluentialOncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“prototype [56], induce senescence in part by indirectly”
BackgroundCellular senescence: when bad things happen to good cells
Campisi, J., & d'Adda di Fagagna, F. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2233 · Cited by 4,441 · cited 1×
“Several lines of evidence indicate that cellular senescence is a potent tumor-suppressive mechanism [4,9,10].”
BackgroundSelf-citationPleiotropy, natural selection, and the evolution of senescence.
Williams, G. C. (1957) · Evolution · doi:10.1111/j.1558-5646.1957.tb02911.x · Cited by 4,279 · cited 1×
“It is now recognized that aging is a consequence of the declining force of natural selection with age [26,70].”
BackgroundDNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688 · cited 1×
“Moreover, human cells that bypass oncogene-induced senescence [58], as well as cells in some human premalignant lesions [73,74], show signs of a persistently activated DDR.”
BackgroundSenescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473 · cited 1×
“Recent findings show that tumors induced to senesce in mice gradually regress [21,22], owing perhaps to infiltration by cells of the innate immune system [22].”
BackgroundSenescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors
Campisi, J. (2005) · Cell · doi:10.1016/j.cell.2005.02.003 · Cited by 2,379
Research works printed but not linked: 80
- Hanahan, 2000, Cell, 100, 57
- Bissell, 2001, Nature Rev Cancer, 1, 46
- Coussens, 2002, Nature, 420, 860
- Campisi, 2007, Nature Rev Molec Cell Biol, 8, 729
- Dimri, 2005, Cancer Cell, 7, 505
- Ben-Porath, 2004, J Clin Invest, 113, 8
- Chau, 2003, Nature Rev Cancer, 3, 130
- Bargonetti, 2002, Curr Opin Oncol, 14, 86
- Braig, 2006, Cancer Res, 66, 2881
- Campisi, 2003, Nature Rev Canc, 3, 339
- Wright, 2001, Curr Opin Genet Dev, 11, 98
- Collins, 2003, Aging Cell, 2, 145
- Lowe, 2003, Curr Opin Genet Dev, 13, 77
- Ohtani, 2004, J Med Invest, 51, 146
- Gil, 2006, Nature Rev Molec Cell Biol, 7, 667
- Collado, 2005, Nature, 436, 642
- Chen, 2005, Nature, 436, 725
- Michaloglou, 2005, Nature, 436, 720
- Braig, 2005, Nature, 436, 660
- Shay, 2004, Oncogene, 23, 2919
- Ventura, 2007, Nature, 445, 661
- Xue, 2007, Nature, 445, 656
- Donehower, 2002, J Cell Physiol, 192, 23
- Faragher, 2000, Biochem Soc Trans, 28, 221
- Kortlever, 2006, Cell Cycle, 5, 2697
- Kirkwood, 2000, Nature, 408, 233
- Campisi, 2005, Cell, 120, 1
- Price, 2002, Aging Cell, 1, 57
- Vasile, 2001, FASEB J, 15, 458
- Matthews, 2006, Circ Res, 99, 156
- Maier, 2004, Genes Dev, 18, 306
- Tyner, 2002, Nature, 415, 45
- Zhang, 2003, Proc Natl Acad Sci U S A, 100, 3251
- Chang, 2002, Proc Natl Acad Sci U S A, 99, 389
- Bavik, 2006, Cancer Res, 66, 794
- Mason, 2004, Oncogene, 23, 9238
- Wajapeyee, 2008, Cell, 132, 363
- Kortlever, 2006, Nat Cell Biol, 8, 877
- Parrinello, 2005, J Cell Sci, 118, 485
- Kuilman, 2008, Cell, 133, 1019
- Acosta, 2008, Cell, 133, 1006
- Krtolica, 2001, Proc Natl Acad Sci U S A, 98, 12072
- Liu, 2007, Cancer Res, 67, 3117
- Parrinello, 2003, Nat Cell Biol, 5, 741
- Hayward, 1995, In Vitro Cell Dev Biol Anim, 31, 14
- Bello, 1997, Carcinogenesis, 18, 1215
- Kaighn, 1979, Invest Urol, 17, 16
- Chang, 1999, Oncogene, 18, 4808
- Schmitt, 2002, Cell, 109, 335
- Tannock, 2004, N Engl J Med, 351, 1502
- Cowin, 2005, Curr Opin Cell Biol, 17, 499
- Kokkinos, 2007, Cells Tissues Organs, 185, 191
- Dhawan, 2005, J Clin Invest, 115, 1765
- Yuan, 2005, Front Biosci, 10, 853
- Badache, 2001, Cancer Res, 61, 383
- Serrano, 1997, Cell, 88, 593
- Di Micco, 2006, Nature, 444, 638
- Mallette, 2007, Genes Dev, 21, 43
- Ancrile, 2007, Genes Dev, 21, 1714
- Yang, 2006, Proc Natl Acad Sci U S A, 103, 16472
- Akhurst, 2001, Trends Cell Biol, 11, 44
- Beausejour, 2003, EMBO J, 22, 4212
- Ossovskaya, 1996, Proc Natl Acad Sci U S A, 93, 10309
- Mantovani, 2006, Nature Rev Immunol, 6, 907
- Jeyapalan, 2007, Mech Ageing Dev, 128, 36
- Dimri, 1995, Proc Natl Acad Sci U S A, 92, 9363
- Paradis, 2001, Hum Pathol, 32, 327
- Melk, 2003, Kidney Int, 63, 2134
- Bruunsgaard, 2001, Curr Opin Hematol, 8, 131
- Williams, 1957, Evolution, 11, 398
- Roberts, 2006, Eur Spine J, 15, 312
- Herbig, 2006, Science, 311, 1257
- Bartkova, 2005, Nature, 434, 864
- Gorgoulis, 2005, Nature, 434, 907
- Kiaris, 2005, Cancer Res, 65, 1627
- Hill, 2005, Cell, 123, 1001
- Coppe, 2006, J Biol Chem, 281, 29568
- Kaminker, 2005, J Cell Sci, 118, 1321
- Kim, 2004, J Biol Chem, 279, 43799
- Krtolica, 2002, Cytometry, 49, 73
Cited by
Items 2,601–2,700 of 4,275
Senescent dermal fibroblasts enhance stem cell migration through CCL 2/ CCR 2 axis
Ohgo, S., Hasegawa, S., Hasebe, Y., Mizutani, H., Nakata, S., & Akamatsu, H. (2015) · Experimental Dermatology · doi:10.1111/exd.12701 · Cited by 12
β-elemene promotes the senescence of glioma cells through regulating YAP-CDK6 signaling.
Yang, D., Xu, X., Wang, X., Feng, W., Shen, X., Zhang, J., Liu, H., Xie, C., Wu, Q., Miao, X., et al. (2021) · PubMed · Cited by 18
Age-associated changes in transcriptional elongation and their effects on homeostasis
Papantonis, A., Antebi, A., Partridge, L., & Beyer, A. (2024) · Trends in Cell Biology · doi:10.1016/j.tcb.2024.11.005 · Cited by 16
Rutecki, S., Szulc, P., Pakuła, M., Uruski, P., Radziemski, A., Naumowicz, E., Moszyński, R., Tykarski, A., Mikuła‐Pietrasik, J., & Książek, K. (2022) · Journal of Ovarian Research · doi:10.1186/s13048-022-01023-y · Cited by 12
Dekker, P., van Baalen, L. M., Dirks, R. W., Slagboom, P. E., van Heemst, D., Tanke, H. J., Westendorp, R. G. J., & Maier, A. B. (2011) · The Journals of Gerontology Series A · doi:10.1093/gerona/glr196 · Cited by 12
“Senescent cells affect the integrity of tissues by altering their morphology and by excreting factors that promote tumor invasiveness (2).”
BackgroundCellular senescence in malignant cells promotes tumor progression in mouse and patient Glioblastoma
Salam, R., Saliou, A., Bielle, F., Bertrand, M., Antoniewski, C., Carpentier, C., Alentorn, A., Capelle, L., Sanson, M., Huillard, E., et al. (2022) · doi:10.1101/2022.05.18.492465 · Cited by 132
Bagheri, Z., Varedi, M., Naghibalhossaini, F., & Omrani, G. R. (2019) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520619666190704102708 · Cited by 11
Myeloid-Derived Suppressor Cells (MDSCs) at the Crossroad of Senescence and Cancer
Talarico, G., Orecchioni, S., Falvo, P., & Bertolini, F. (2025) · Cancers · doi:10.3390/cancers17132251 · Cited by 14
“These cells, characterized by SASP, secrete a complex cocktail of pro-inflammatory cytokines, chemokines, growth factors, and proteases that can disrupt local tissue homeostasis, promote chronic inflammation, and enhance tumor growth [5,24].”
Small, S. H., Tang, E. J., Ragland, R. L., Ruzankina, Y., Schoppy, D. W., Mandal, R. S., Glineburg, M. R., Ustelenca, Z., Powell, D. J., Simpkins, F. A., et al. (2021) · Science Signaling · doi:10.1126/scisignal.aba2611 · Cited by 14
Endoplasmic Reticulum Stress Induced Proliferation Remains Intact in Aging Mouse β-Cells
Snyder, J. T., Darko, C., Sharma, R. B., & Alonso, L. C. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.734079 · Cited by 13
“Although loss of p16INK4a was not sufficient to restore the proliferative response to glucose in mouse islets (24), the impact of UPR activation on b-cell senescence, SASP or BMI1 remain unknown.”
BackgroundThe paracrine effects of fibroblasts on Doxorubicin-treated breast cancer cells
Fourie, C., Davis, T., Kriel, J., & Engelbrecht, A. (2019) · Experimental Cell Research · doi:10.1016/j.yexcr.2019.05.020 · Cited by 13
A Senomorphic‐Conjugated Scaffold for Application of Senescent Cells in Regenerative Medicine
Deng, W., Jun-ichiro, J. O., Tanaka, T., Morikuni, H., Hashimoto, Y., Matsumoto, N., & Honda, Y. (2023) · Advanced Therapeutics · doi:10.1002/adtp.202200276 · Cited by 14
Potential role of cGAS/STING pathway in regulating cancer progression
Dhanisha, S. S., & Guruvayoorappan, C. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103780 · Cited by 12
Alam, M. T., Mansoor, M. A. M., Ashiqueali, S., Golusiński, P., Golusińska-Kardach, E., Strzelczyk, J. K., Rubiś, B., Golusiński, W., & Masternak, M. M. (2025) · Cancers · doi:10.3390/cancers17244024 · Cited by 16
“Prolonged SASP activity, however, can paradoxically aid in tumor progression through chronic inflammation and stromal remodeling, even though the SASP has robust tumor-alleviating effects in the early stages of cancer development [64,65].”
Senescent cells in tissue engineering
Chin, A. F., & Elisseeff, J. H. (2022) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2022.102737 · Cited by 13
The role of sirtuins in dermal fibroblast function
Gilbert, M. M., Mathes, S. C., Mahajan, A. S., Rohan, C. A., Travers, J. B., & Thyagarajan‐Sahu, A. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1021908 · Cited by 19
“Our current data indicating that the mRNA levels of all seven sirtuins were diminished in senescent normal human fibroblast suggest that these bioactive agents could be playing a role in the fibroblasts SASP.”
BackgroundInfluentialVarious stress stimuli rewire the profile of liver secretome in a p53-dependent manner
Charni‐Natan, M., Solomon, H., Molchadsky, A., Jacob-Berger, A., Goldfinger, N., & Rotter, V. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0697-4 · Cited by 12
Cellular senescence: Silent operator and therapeutic target in cancer
Ramu, D., Teoh, W. S., Hirpara, J. L., & Pervaiz, S. (2021) · IUBMB Life · doi:10.1002/iub.2460 · Cited by 13
“Corroborating this, the application of genotoxic stress promoted SASP acquisition in normal epithelial and fibroblast cells, as well as in tumor cells treated with genotoxic agents, which involved activation of the oncogene Ras or p53 loss.(44) Likewise, studies revealed that, upon exposure to chemical carcinogens, li…”
BackgroundZayed, H. (2020) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2020.103806 · Cited by 12
Skeletal Senescence with Aging and Type 2 Diabetes
Farr, J. N. (2023) · Endocrinology and Metabolism · doi:10.3803/enm.2023.1727 · Cited by 14
“and matrix degrading/remodeling proteins [17-19].”
Nacarelli, T., Azar, A., Potnis, M., Johannes, G., Mell, J. C., Johnson, F. B., Brown‐Borg, H. M., Noguchi, E., & Sell, C. (2022) · Molecular Biology of the Cell · doi:10.1091/mbc.e20-08-0523 · Cited by 11
Sugiyama, Y., Harada, T., Kamei, Y., Yasuda, T., Mashimo, T., Nishikimi, A., & Maruyama, M. (2023) · Experimental Gerontology · doi:10.1016/j.exger.2023.112130 · Cited by 12
Kamal, M. J., Joanisse, S., & Parise, G. (2023) · GeroScience · doi:10.1007/s11357-023-00929-9 · Cited by 14
“Meanwhile, senescent cells are continuously releasing SASP factors that reinforce the senescence signal from the host cell, but also act on adjacent cells that may not yet be senescent [39, 40].”
Skwarska, A., Ramachandran, S., Dobrynin, G., Leszczyńska, K. B., & Hammond, E. M. (2017) · Oncotarget · doi:10.18632/oncotarget.16102 · Cited by 12
“Mitoxantrone was shown to induce a senescence-associated secretory phenotype (SASP) in several prostate cancer cell lines, and this was increased in the absence of functional p53 [18].”
BackgroundZhou, L., DeMarco, K. D., Murphy, K. C., Wu, Z., Li, J., Johnson, C., Liu, B., Giwa, H. K., Ma, B., Bhalerao, N., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-1212 · Cited by 22
Mechanisms of Senescence in Cancer: Positive and Negative Aspects of Cancer Cells Senescence
Zaczek, A., Kalenik, S., & Rodacka, A. (2023) · Cellular Physiology and Biochemistry · doi:10.33594/000000671 · Cited by 12
Premature senescence and cardiovascular disease following cancer treatments: mechanistic insights
Jain, A., Casanova, D., Padilla, A. V., Paniagua-Bojorges, A., Kotla, S., Ko, K. A., Samanthapudi, V. S. K., Chau, K. M., Nguyen, M. T., Wen, J. J., et al. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1212174 · Cited by 13
IL-1 and senescence: Friends and foe of EGFR neutralization and immunotherapy
Romaniello, D., Gelfo, V., Pagano, F., Sgarzi, M., Morselli, A., Girone, C., Filippini, D. M., D’Uva, G., & Lauriola, M. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1083743 · Cited by 15
“…and IL-8 are among the main soluble factors found in the SASP, responsible for increasing the invasiveness of a panel of breast cancer cell lines (Coppé et al., 2008); or for impairing the response to EGFR neutralization by monoclonal antibody (Gelfo et al., 2016; 2018; 2020) and kinase…”
BackgroundInfluentialChan, K. T., Paavolainen, L., Hannan, K. M., George, A. J., Hannan, R. D., Simpson, K. J., Horváth, P., & Pearson, R. B. (2016) · Assay and Drug Development Technologies · doi:10.1089/adt.2016.739 · Cited by 11
Chen, R., Zhang, X., Zhu, X., Wang, C., & Xu, W. (2023) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-022-03463-0 · Cited by 12
“Cellular senescence is usually defined as irreversible cell cycle arrest due to replication stress and senescence [2], and the senescence-associated secretory phenotype (SASP) is an important feature of cellular senescence, which secretes a series of cytokines such as pro-inflammatory factors, growth factors, chemokin…”
BackgroundDas, M., & Kale, V. P. (2021) · Cell Biology International · doi:10.1002/cbin.11691 · Cited by 11
“Pieces of evidence suggest that senescent cells also release different types of secretory molecules like growth factors, cytokines, chemokines, and matrix metalloprotease, and so on (Coppé et al., 2008; Rodier et al., 2009).”
BackgroundRangel-Zúñiga, O. A., Corina, A., Lucena-Porras, B., Cruz-Teno, C., Gómez-Delgado, F., Jiménez-Lucena, R., Alcalá-Díaz, J. F., Haro-Mariscal, C., Yubero-Serrano, E. M., Delgado-Lista, J., et al. (2016) · Experimental Gerontology · doi:10.1016/j.exger.2016.07.015 · Cited by 11
Cellular senescence and developmental defects
Klein, A., Rhinn, M., & Keyes, W. M. (2023) · FEBS Journal · doi:10.1111/febs.16731 · Cited by 14
NKAP Regulates Senescence and Cell Death Pathways in Hematopoietic Progenitors
Shapiro, M. J., Anderson, J., Lehrke, M. J., Chen, M., Holte, M. N., & Shapiro, V. S. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00214 · Cited by 13
Park, J.-J., Oh, K., Lee, G.-W., Bang, G., Park, J., Kim, H.-B., Kim, J. Y., Shin, E., & Kim, E. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-00966-6 · Cited by 17
“The SASP, which is regarded as a major pathogenic mechanism, exerts an effect on surrounding cells through the secretion of many in fl ammatory mediators and growth factors 7 .”
A novel pathway links telomeres to NK-cell activity
Cherfils‐Vicini, J., Zizza, P., Gilson, É., & Biroccio, A. (2014) · OncoImmunology · doi:10.4161/onci.27358 · Cited by 11
“This conclusion was based on the following results: (1) TERF2-deficient cancer cells rapidly stop dividing upon injection into mice, are unable to promote angiogenesis and recruit NK cells; (2) the recruitment of NK cells is repressed or promoted by TERF2-overexpressing or TERF2deficient cells, respectively; and (3) t…”
BackgroundResultThe senescent mesothelial matrix accentuates colonization by ovarian cancer cells
Thapa, B. V., Banerjee, M., Glimm, T., Saini, D. K., & Bhat, R. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-05017-x · Cited by 14
“Senescent cells are well known to secrete a gamut of soluble cytokines that may regulate the attraction and proliferation of cells surrounding them, a phenomenon referred to as senescence-associated secretory phenotype [21, 22].”
BackgroundBayer, A. L., Pietruska, J. R., Farrell, J., McRee, S. K., Alcaide, P., & Hinds, P. W. (2022) · Cancers · doi:10.3390/cancers14030572 · Cited by 14
“The senescence-associated secretory phenotype, or “SASP”, involves an enhanced secretion of inflammatory mediators that has been shown to drive neoplastic changes and harmful inflammation under certain circumstances [2,8,9].”
BackgroundThe ING1a model of rapid cell senescence
Bertschmann, J., Thalappilly, S., & Riabowol, K. T. (2018) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2018.06.004 · Cited by 14
Senescent macrophages in tumor: phenotypes, roles, and interventions
Shen, W., Huang, Y., Yang, X., Zhang, Y., Pan, Y., Xiao, Y., Wang, J., Wang, C., Mao, W., & Zhao, A. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08000-5 · Cited by 17
“This evasion fosters the accumulation of senescent cells, which disrupts the tissue microenvironment and may contribute to the onset of various ARDs, including malignancies [1, 7, 10, 13].”
Aging and oral squamous cell carcinoma development: the role of cellular senescence
Niklander, S. E., Aránguiz, P., Faunes, F., & Flores, R. (2023) · Frontiers in Oral Health · doi:10.3389/froh.2023.1285276 · Cited by 20
Rothmiller, S., Jäger, N., Meier, N., Meyer, T., Neu, A., Steinritz, D., Thiermann, H., Scherer, M. A., Rummel, C., Mangerich, A., et al. (2021) · Archives of Toxicology · doi:10.1007/s00204-020-02946-5 · Cited by 12
“One very important aspect and biomarker of senescent cells is their secretome called SASP (Coppé et al. 2008).”
BackgroundInfluentialThe potential of targeting Sin3B and its associated complexes for cancer therapy
Cantor, D. J., & David, G. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1386655 · Cited by 11
“matrix metalloproteases collectively termed the SASP [75,76].”
BackgroundInfluentialDetecting Markers of Therapy-Induced Senescence in Cancer Cells
Fan, D. N.-Y., & Schmitt, C. A. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6670-7_4 · Cited by 14
“This is of particular importance, since the largely NF-κB-driven pro-inflammatory and matrix-remodeling components of the SASP may affect adjacent (pre-)tumor cells, profoundly alter the tumor microenvironment and attract host immune cells (1-4, 12, 19, 21, 22).”
BackgroundYu, J., Zhang, M., Li, T., Gao, W., Yang, Z., Wang, K., Liu, Z., Zhu, S., Wen, S., Zhao, Y., et al. (2024) · Oncogene · doi:10.1038/s41388-024-03132-y · Cited by 14
“…growth arrest, maintains metabolically active and secretes a variety of proin fl ammatory and immune-modulatory cytokines and chemokines such as IL6 and CXCL8 in the tumor microenvironment that mediate paracrine effects on neighboring non-senescent cells and promoting the tumor outgrowth [16 – 22].”
Tumor senescence leads to poor survival and therapeutic resistance in human breast cancer
Zhai, J., Han, J., Li, C., Lv, D., Ma, F., & Xu, B. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1097513 · Cited by 13
A biosensory μvessel-gravity device for advancing vascular analysis in space medicine
Xu, K., Wang, X., Bai, H., Wu, G., Zhang, W., Zhou, J., Zhang, P., Zhang, X., Peng, B., Voelcker, N. H., et al. (2024) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2024.116923 · Cited by 13
Hattori, H., Takaoka, K., Ueta, M., Oshitani, M., Tamaoka, J., Noguchi, K., & Kishimoto, H. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.12320 · Cited by 13
The Role of the Microenvironment in Tumor Initiation, Progression, and Metastasis
Ghajar, C. M., Correia, A. L., & Bissell, M. J. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4066-6.00016-0 · Cited by 12
Strategies of the War on Cancer: To Kill or to Neutralize?
Lichtenstein, A. V. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2018.00667 · Cited by 11
“extracellular vesicles [37-42], miRNAs [43], free DNA [44], and cancer-related neurogenetic factors [45].”
BackgroundSenescence in cancer: Hallmarks, paradoxes, and therapeutic promise
Hinterleitner, C., Goldberg, H. V., McHugh, D., Barthet, V. J. A., Filliol, A. A., & Lowe, S. W. (2026) · Cell · doi:10.1016/j.cell.2026.03.005 · Cited by 23
“These and related observations ultimately led to the conceptualization of the “senescence-associated secretory phenotype (SASP)”, a coordinated program of proteases, growth factors, and immune modulatory cytokines with the capacity to remodel and modulate immune survelliance 21-23 .”
COVID-19 inhibits spermatogenesis in the testes by inducing cellular senescence
Wang, Z., Ma, Y., Chen, Z., Yang, R., Liu, Q., Pan, J., Wang, J., Liu, Y., Zhou, M., Zhang, Y., et al. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2022.981471 · Cited by 10
Immunosuppression in inflammatory melanoma: can it be resisted by adoptively transferred T cells?
Auphan‐Anezin, N., Verdeil, G., Grange, M., Soudja, S. M., Wehbe, M., Buferne, M., Mas, A., & Schmitt‐Verhulst, A. (2012) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12056 · Cited by 11
“…circuit appears to be initiated by oncogenic H-ras (O’Hayer et al., 2009), which, in the absence of the senescence promoting p16/Arf pathway (Coppe et al., 2008; Kwong et al., 2009), leads to expression of pro-inflammatory genes as well as to genes characterizing an EMT-like process and…”
BackgroundLack of a p16/ARF locus in fish genome may underlie senescence resistance in the fish cell line, EPC
Futami, K., Sato, S., Maita, M., & Katagiri, T. (2022) · Developmental & Comparative Immunology · doi:10.1016/j.dci.2022.104420 · Cited by 11
Immunoregulatory network and cancer-associated genes: molecular links and relevance to aging
Tăcutu, R., Budovsky, A., & Yanai, H. (2011) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 11
Gaps in Aging Research as it Applies to Rheumatologic Clinical Care
Makris, U. E., Misra, D., & Yung, R. L. (2016) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2016.08.009 · Cited by 12
Ahn, C. H., Choi, E. H., Oh, T. J., & Cho, Y. M. (2020) · Obesity Surgery · doi:10.1007/s11695-020-04406-6 · Cited by 11
“Abbreviations IT, ileal transposition; GLP-1, glucagon-like peptide-1; RYGB, Roux-en-Y gastric bypass; T2DM, type 2 diabetes mellitus; PYY, peptide YY; SASP, senescence-associated secretary phenotype; HOMAIR, homeostatic model assessment for insulin resistance; AUC, area under the curve; OGTT, oral glucose tolerance t…”
BackgroundOspina-Muñoz, N., & Vernot, J. (2020) · Tumor Biology · doi:10.1177/1010428320979438 · Cited by 12
Immune senescence in multiple myeloma—a role for mitochondrial dysfunction?
Seymour, F., Carmichael, J., Taylor, C., Parrish, C., & Cook, G. (2022) · Leukemia · doi:10.1038/s41375-022-01653-7 · Cited by 11
Sun, H., Yang, D., Mi, J., Yu, Y.-Q., & Qiu, L. (2019) · Connective Tissue Research · doi:10.1080/03008207.2019.1620225 · Cited by 11
A flow-cytometry-based assessment of global protein synthesis in human senescent cells
Lee, Y., Kim, J., Jeon, T., Roh, K., Kim, M.-S., & Kang, C. (2021) · STAR Protocols · doi:10.1016/j.xpro.2021.100809 · Cited by 11
NAD+ metabolism controls inflammation during senescence
Nacarelli, T., & Zhang, R. (2019) · Molecular & Cellular Oncology · doi:10.1080/23723556.2019.1605819 · Cited by 16
“A key tumor suppressive role of p53 is suppression of NFkB activity and the pro-inflammatory SASP.(7) Indeed, inhi-”
BackgroundWu, S., Li, Y., Zhao, X., Shi, F., & Chen, J. (2024) · Clinical Proteomics · doi:10.1186/s12014-024-09480-x · Cited by 14
“However, none of the biomarkers in our study were present in senescence-associated secretory phenotypes (SASPs) previously identified in several types of senescent cells induced by senescence-inducing stimuli in vitro [23, 24].”
BackgroundThe role of gender and labour status in immunosenescence of 65+ Polish population
Dudkowska, M., Janiszewska, D., Karpa, A., Broczek, K., Dabrowski, M., & Sikora, E. (2017) · Biogerontology · doi:10.1007/s10522-017-9702-z · Cited by 11
“Increase secretion of these cytokines is a components of the so called senescence associated secretory phenotype (SASP) characteristic for senescence cells (Coppe et al. 2008).”
BackgroundPAI-1 is a common driver of aging and diverse diseases
Khoddam, A., Miyata, T., & Vaughan, D. E. (2025) · Biomedical Journal · doi:10.1016/j.bj.2025.100892 · Cited by 12
“PAI-1's expression surges in senescent cells, contributing to the senescence-associated secretory phenotype (SASP), a pro-inflammatory milieu rich in cytokines (e.g., IL-6, IL-8), chemokines (e.g., CCL2), and matrix metalloproteinases (MMPs) that perpetuate tissue dysfunction [26].”
The Dual Role of Senescence in Tumorigenesis
Chuaire, L., Sánchez, M. C., & Ramírez-Clavijo, S. R. (2010) · International Journal of Morphology · doi:10.4067/s0717-95022010000100006 · Cited by 13
“…Colombia microenvironment -autocrine and paracrine- generated by these factors induced changes in the activity of nearby cells, as was confirmed by Coppé et al. (2008), who proved that a conditioned medium obtained from cultured senescent fibroblasts is capable of inducing the proliferation of…”
BackgroundInfluentialCellular Senescence and Tumor Suppression
Adams, P. D., & Sedivy, J. M. (2010) · Springer eBooks · doi:10.1007/978-1-4419-1075-2 · Cited by 10
Development of a novel senolytic by precise disruption of FOXO4-p53 complex
Tripathi, U., Chaib, S., Gerdes, E. O. W., Hogan, K. A., & Zhu, Y. Z. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103693 · Cited by 11
Phosphoinositide species and filamentous actin formation mediate engulfment by senescent tumor cells
Frey, W. D., Anderson, A. Y., Lee, H., Nguyen, J. B., Cowles, E., Lu, H., & Jackson, J. G. (2022) · PLoS Biology · doi:10.1371/journal.pbio.3001858 · Cited by 11
Banerjee, P., Olmsted‐Davis, E. A., Deswal, A. M., Nguyen, M. T. H., Koutroumpakis, E., Palaskas, N., Lin, S. H., Kotla, S., Reyes‐Gibby, C. C., Yeung, S. J., et al. (2022) · The Journal of Cardiovascular Aging · doi:10.20517/jca.2022.13 · Cited by 11
Molecular damage associated with ageing drives inflammation in cardiovascular disease
Herman, A. B., Candia, J., Wilson, D. M., Donegà, S., Picard, M. A., & Ferrucci, L. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01253-3 · Cited by 17
“…effective interventions to prevent and treat CVD. Strikingly, 28 of the 50 plasma proteins identified as predictors of cardiovascular outcomes have been previously identified as SASP members in preclinical studies of cellular senescence, and seven others are receptors of SASP members 108–113 (Fig.”
Sun, Y., Zhang, J., Chen, B., Yang, Y., Li, H., Niu, X., Li, Q., Wu, W., Xie, Z., Chen, Y., et al. (2020) · Journal of Material Science and Technology · doi:10.1016/j.jmst.2020.03.014 · Cited by 10
Self-citationCai, X., Zhang, Y., Zhu, W., & Gu, N. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115587 · Cited by 13
Gwak, H., Hong, S., Lee, S. H., Kim, I. W., Kim, Y., Kim, H., Pahk, K. J., & Kim, S. Y. (2025) · Aging Cell · doi:10.1111/acel.14486 · Cited by 14
“However, it has been suggested that the SASP is not induced by p16-or p21-dependent cell cycle arrest (Coppe et al. 2008).”
Cholesterol Accumulation Promotes Photoreceptor Senescence and Retinal Degeneration
Terao, R., Sohn, B. S., Yamamoto, T., Lee, T. J., Colasanti, J. J., Pfeifer, C. W., Lin, J. B., Santeford, A. C., Yamaguchi, S., Yoshida, M., et al. (2024) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.65.10.29 · Cited by 11
“20 Senotherapy by genetic and pharmacological removal of senescent cells (senolytics) ameliorates age-related phenotypes and neurodegenerative diseases.”
BackgroundSimon, K. W., Mukundan, A., Dewundara, S., Remmen, H. V., Dombkowski, A. A., & Cabelof, D. C. (2009) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2009.07.007 · Cited by 12
“Coppe et al. (2008) have found that loss of p53 increases the risk that cells exposed to genotoxic stress will escape senescence, and have demonstrated that these cells express a highly amplified secretory phenotype, which can increase cancer risk through a cell-nonautonomous mechanism.”
BackgroundTian, Y.-T., Ma, L.-P., Ding, C.-Y., Liu, M.-M., Wang, S.-N., Tian, M., Gao, L., & Liu, Q.-J. (2022) · International Journal of Radiation Biology · doi:10.1080/09553002.2022.2055799 · Cited by 10
Pèrié, L., Houël, C., Zambon, A., Guéré, C., Vié, K., Leroy‐Dudal, J., Vendrely, C., Agniel, R., Carreiras, F., & Picot, C. R. (2024) · Experimental Cell Research · doi:10.1016/j.yexcr.2024.114251 · Cited by 12
Saleh, T., Naffa, R. G., Barakat, N. A., Ismail, M. A., Alotaibi, M. R., & Alsalem, M. (2024) · Neurotoxicity Research · doi:10.1007/s12640-024-00690-7 · Cited by 11
“Lastly, a major limitation for this experiment is that we measured the expression of the SASP factors at the gene level, rather than at the protein level, although this approach is generally accepted in the scientific literature (Coppé et al. 2008).”
Li, J., Wang, J., Liu, D., Tao, C., Zhao, J., & Wang, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1018942 · Cited by 9
Exploring natural killer cell immunology as a therapeutic strategy in lung cancer
Hess, J. B., Sutherland, K. D., & Best, S. A. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-765 · Cited by 11
“NK cells are attracted to senescence associated secretory phenotype (SASP) chemokines involved in recruitment (CCL2, CCL4, CCL5, CXCL10, CX3CL1) and cytokines to induce proliferation (IL-15, IL-18, TNF-α) (90-92) released by senescent cells (93).”
BackgroundOverdosage of Methylparaben Induces Cellular Senescence In Vitro and In Vivo
Cha, H. J., Bae, S., Kim, K., Kwon, S. B., An, I.-S., Ahn, K. J., Ryu, J., Kim, H.-S., Ye, S., Kim, B., et al. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.405 · Cited by 11
Eakin, A., McErlain, T., Burke, A., Eaton, A., Tipping, N., Allocca, G., & Branco, C. M. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00799 · Cited by 14
Lewis, L., Valvi, D., Gedaly, R., & Martí, F. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1621759 · Cited by 13
“…factors, and proteases that can induce secondary senescence in surrounding healthy cells and tissues – a phenomenon known as the senescence-associated secretory phenotype (SASP) (111, 112), which can contribute to amplify the chronic in fl ammation that drives aging and its associated pathologies.”
Possible molecular mechanisms underlying the development of atherosclerosis in cancer survivors
Banerjee, P., Rosales, J. E., Chau, K. M., Nguyen, M. T., Kotla, S., Lin, S. H., Deswal, A. M., Dantzer, R., Olmsted‐Davis, E. A., Nguyen, H., et al. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1186679 · Cited by 11
Kamii, M., Kamata, R., Saitô, H., Yamamoto, G., Mashima, C., Yamauchi, T., Nakao, T., Sakae, Y., Yamamori-Morita, T., Nakai, K., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-00336-4 · Cited by 13
“The p53/p21 and p16/RB pathways are involved in senescence-associated antiproliferative effects 22 .”
InfluentialA human neuron Alzheimer’s disease model reveals barriers to senolytic translatability
Walton, C. C., Wang, E. Y., Lee, S., Siebrand, C. J., Bergo, N. J., Mayeri, Z., & Andersen, J. K. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01822-7 · Cited by 10
“…compatible with the preferential elimination of senescent-like neurons and astrocytes in an Aβ in vitro model of AD: The immune system naturally eliminates senescent cells through senescence immune surveillance, primarily mediated by NK cells, CD8+ cytotoxic T-cells (CTT), and macrophages 34 .”
Targeting immunosenesence promotes clearance of senescent cells
Tizazu, A. M., Tessema, E. A., & Cexus, O. (2025) · Immunity & Ageing · doi:10.1186/s12979-025-00518-8 · Cited by 15
Senescence in a cell culture model for burn wounds
Kerschbaum, S., Wegrostek, C., Riegel, E., & Czerny, T. (2021) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2021.104674 · Cited by 11
Do cell-autonomous and non-cell-autonomous effects drive the structure of tumor ecosystems?
Tissot, T., Újvári, B., Solary, É., Lassus, P., Roche, B., & Thomas, F. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.01.005 · Cited by 12
Identifying the miRNA Signature Association with Aging-Related Senescence in Glioblastoma
Mutharasu, G., Murugesan, A., Saravanan, K. M., Yli-Harja, O. P., & Kandhavelu, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020517 · Cited by 10
“This mediates cellular response to stress arising from RAS and p53 tumor suppressor [38], and DNA damage signaling, and triggers the senescence-associated inflammatory cytokine secretion [39].”
BackgroundEbert, R., Weißenberger, M., Braun, C., Wagenbrenner, M., Herrmann, M., Müller-Deubert, S. M., Krug, M., Jakob, F. J., & Rudert, M. (2021) · Journal of Orthopaedic Research® · doi:10.1002/jor.25041 · Cited by 10
“However, these proinflammatory factors are also part of the SASP, which is known to accelerate the senescence‐associated proliferation stop in MSC and can improve tissue repair, given that this inflammatory process consists of short‐term upregulation and timely inflammation resolution.(27) In contrast, long‐term up‐ o…”
BackgroundKang, T., Moore, E. C., Kopania, E. E. K., King, C. D., Schilling, B., Campisi, J., Good, J. M., & Brem, R. B. (2023) · G3: Genes, Genomes, Genetics · doi:10.1093/g3journal/jkad091 · Cited by 10
“In the resulting profiles, we inspected genes of the 330 SASP immune-stimulatory program (4), and found that this gene cohort was induced more 331 highly in M.”
BackgroundMethodSenolytic CAR T cells reverse aging-associated defects in intestinal regeneration and fitnessPreprint
Eskiocak, O., Chowdhury, S., Shah, V., Nnuji-John, E., Chung, C., Boyer, J. A., Harris, A. S., Habel, J., Sadelain, M., Beyaz, S., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.19.585779 · Cited by 11
Suppression of p16 alleviates the senescence-associated secretory phenotype
(2020) · doi:10.1101/2020.08.19.257717 · Cited by 84
Targeted Therapeutics Delivery by Exploiting Biophysical Properties of Senescent Cells
Low, J., Chan, B., & Tay, A. K. P. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202107990 · Cited by 11
Ma, X., Gao, Y., Liu, J., Xu, L., Liu, W., Huna, A., Wang, X., & Gong, W. (2022) · IUBMB Life · doi:10.1002/iub.2651 · Cited by 10
“It has been demonstrated that CS plays key roles in tumor suppression or progression depending on the SASP composition.(6) Mechanistically, CS is regulated by multiple afferent signaling pathways, among which the most commonly studied ones are p53-p21 and p16 downstream cascades.”
BackgroundNOTCH-mediated non-cell autonomous regulation of chromatin structure during senescence
(2017) · doi:10.1101/212829 · Cited by 102
Iop, L., Sasso, E. D., Schirone, L., Forte, M., Peruzzi, M., Cavarretta, E., Palmerio, S., Gerosa, G., Sciarretta, S., & Frati, G. (2017) · Mediators of Inflammation · doi:10.1155/2017/7953486 · Cited by 10
Metadata
- Authors
- Coppé, J.-P., Patil, C. K., Rodier, F., Sun, Y., Muñoz, D. P., Goldstein, J., Nelson, P. S., Desprez, P.-Y., & Campisi, J.
- Affiliations
- Lawrence Berkeley National Laboratory (US)
- Fred Hutch Cancer Center (US)
- Buck Institute for Research on Aging (US)
- Corresponding author
- Campisi, Judith
- Venue
- PLoS Biology
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-12-02
- Volume
- 6
- Issue
- 12
- Pages
- e301
- ISSN
- 1544-9173 (ISSN-L)
- 1545-7885
- PMC
- PMC2592359
- OpenAlex
- W239602587
- Cited by
- 302
- References
- 81
- Citations by year
- 2025: 16 · 2024: 29 · 2023: 30 · 2022: 38 · 2021: 49 · 2020: 26 · 2019: 15 · 2018: 12 · 2017: 16 · 2016: 16 · 2015: 11 · 2014: 8 · 2013: 4 · 2012: 9
- FWCI
- 5.19
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Biology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- University of North Texas Digital Library (University of North Texas) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Lawrence Berkeley National Laboratory
- Funders
- Larry L. Hillblom Foundation
- University of Washington
- National Institutes of Health (AG09909, AG017242, CA126540, AG000266)
- National Institute on Aging (R56AG009909, AG017242, AG-09909, R37AG009909, AG000266, P01AG017242, T32AG000266)
- National Cancer Institute (CA126540, CA 97186, U54CA126540, P50CA097186)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- senescence-associated secretory phenotype, cellular senescence, genotoxic stress, oncogenic Ras, p53 tumor suppressor, paracrine signaling, interleukin-6, interleukin-8, epithelial-mesenchymal transition, tumor invasion, prostate cancer chemotherapy, tissue microenvironment, age-related cancer
- MeSH terms
- Adult, Aging, Antineoplastic Agents, Cells, Cultured, Epithelial Cells, Fibroblasts, Humans, Infant, Newborn, Male, Neoplasm Invasiveness, Neoplasms, Phenotype, Prostatic Neoplasms, Genes, ras, Interleukin-6, Tumor Suppressor Protein p53, Interleukin-8, Cellular Senescence, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.